{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:27:01Z","timestamp":1790000821162,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s11523-025-01149-1","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T02:22:32Z","timestamp":1746584552000},"page":"651-661","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Teclistamab Dosing in Responders: Modeling and Simulation Results from the MajesTEC-1 Study in Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1007","volume":"20","author":[{"given":"Yue","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia A. Quijano","family":"Card\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liviawati","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalla","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaming","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos P\u00e9rez","family":"Ruixo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeksha","family":"Vishwamitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Chastain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh N.","family":"Samtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weirong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahor","family":"Haddish-Berhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"1149_CR1","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387:2232\u201344.","journal-title":"N Engl J Med"},{"key":"1149_CR2","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367.","journal-title":"Nat Med"},{"key":"1149_CR3","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41:1265\u201374.","journal-title":"J Clin Oncol"},{"key":"1149_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495\u2013505.","journal-title":"N Engl J Med"},{"key":"1149_CR5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"1149_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1146\/annurev-med-050522-033815","volume":"75","author":"AL Garfall","year":"2024","unstructured":"Garfall AL. New biological therapies for multiple myeloma. Annu Rev Med. 2024;75:13\u201329.","journal-title":"Annu Rev Med"},{"key":"1149_CR7","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.24.01008","volume":"42","author":"N Bumma","year":"2024","unstructured":"Bumma N, Richter J, Jagannath S, et al. Linvoseltamab for treatment of relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42:2702\u201312.","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"1149_CR8","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1182\/blood-2023-181228","volume":"142","author":"A Chari","year":"2023","unstructured":"Chari A, Oriol A, Krishnan A, et al. Efficacy and safety of less frequent\/lower intensity dosing of talquetamab in patients with relapsed\/refractory multiple myeloma: results from the phase 1\/2 MonumenTAL-1 study. Blood. 2023;142(suppl 1):1010.","journal-title":"Blood"},{"key":"1149_CR9","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1182\/blood-2022-157547","volume":"140","author":"AM Lesokhin","year":"2022","unstructured":"Lesokhin AM, Richter J, Trudel S, et al. Enduring responses after 1-year, fixed-duration cevostamab therapy in patients with relapsed\/refractory multiple myeloma: early experience from a phase I study. Blood. 2022;140:4415\u20137.","journal-title":"Blood"},{"key":"1149_CR10","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Karlin L, Benboubker L, et al. Durability of responses with biweekly dosing of teclistamab in patients with relapsed\/refractory multiple myeloma achieving a clinical response in the MajesTEC-1 study. J Clin Oncol. 2023;41(16_suppl):8034.","DOI":"10.1200\/JCO.2023.41.16_suppl.8034"},{"key":"1149_CR11","unstructured":"US FDA prescribing information. TECVAYLI\u2122 (teclistamab). Vol. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761291s000lbl.pdf. Accessed 23 July 2024"},{"key":"1149_CR12","unstructured":"TECVAYLI, (teclistamab). Summary of product characteristics. Leiden: Janssen Biologics BV; 2024."},{"key":"1149_CR13","doi-asserted-by":"crossref","unstructured":"Garfall AL, Nooka AK, van de Donk NWCJ, et al. Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42(16_suppl):7540.","DOI":"10.1200\/JCO.2024.42.16_suppl.7540"},{"key":"1149_CR14","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cncr.35107","volume":"130","author":"AK Nooka","year":"2024","unstructured":"Nooka AK, Rodriguez C, Mateos MV, et al. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study. Cancer. 2024;130:886\u2013900.","journal-title":"Cancer"},{"key":"1149_CR15","unstructured":"Janssen Pharmaceutical Companies. European Commission approves reduced dosing frequency for Janssen\u2019s bispecific antibody TECVAYLI\u00ae (teclistamab) [media release] https:\/\/www.jnj.com\/media-center\/press-releases\/european-commission-approves-reduced-dosing-frequency-for-janssens-bispecific-antibody-tecvayli-teclistamab. Accessed 1 Aug 2024."},{"key":"1149_CR16","unstructured":"Johnson & Johnson. TECVAYLI\u00ae (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma [media release]. https:\/\/www.jnj.com\/media-center\/press-releases\/tecvayli-teclistamab-cqyv-biweekly-dosing-approved-by-the-u-s-fda-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma. Accessed 1 Aug 2024."},{"key":"1149_CR17","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s11523-022-00893-y","volume":"17","author":"S Girgis","year":"2022","unstructured":"Girgis S, Lin SXW, Pillarisetti K, et al. Translational modeling predicts efficacious therapeutic dosing range of teclistamab for multiple myeloma. Target Oncol. 2022;17:433\u20139.","journal-title":"Target Oncol"},{"key":"1149_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13717","volume":"17","author":"Y Guo","year":"2024","unstructured":"Guo Y, Quijano Card\u00e9 NA, Kang L, et al. Teclistamab: mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17: e13717.","journal-title":"Clin Transl Sci"},{"key":"1149_CR19","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11523-023-00989-z","volume":"18","author":"X Miao","year":"2023","unstructured":"Miao X, Wu LS, Lin SXW, et al. Population pharmacokinetics and exposure-response with teclistamab in patients with relapsed\/refractory multiple myeloma: results from MajesTEC-1. Target Oncol. 2023;18:667\u201384.","journal-title":"Target Oncol"},{"key":"1149_CR20","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","volume":"4","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, Powers G, Luistro L, et al. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020;4:4538\u201349.","journal-title":"Blood Adv"},{"key":"1149_CR21","unstructured":"Niu J, Guo Y, Peng T, et al. Development of a platform quantitative systems pharmacology (QSP) model to support the clinical development of T cell redirecting bispecific antibodies for patients with relapsed\/refractory multiple myeloma. In: American conference on pharmacometrics (ACoP) 14. National Harbor, MD. 2023. ISSN: 2688-3953."},{"key":"1149_CR22","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk N, et al. Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398:665\u201374.","journal-title":"Lancet"},{"issue":"4","key":"1149_CR23","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1182\/bloodadvances.2022007625","volume":"7","author":"S Girgis","year":"2023","unstructured":"Girgis S, Wang Lin SX, Pillarisetti K, et al. Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed\/refractory multiple myeloma. Blood Adv. 2023;7(4):644\u20138.","journal-title":"Blood Adv"},{"key":"1149_CR24","unstructured":"Beal S, Boeckmann L, Bauer R, Sheiner L. NONMEM 7.4 User\u2019s Guides. https:\/\/nonmem.iconplc.com\/nonmem743\/guides. Accessed 1 Aug 2024."},{"key":"1149_CR25","unstructured":"The R project for statistical computing. Vol. 2022. https:\/\/www.r-project.org\/. Accessed 1 Aug 2024."},{"key":"1149_CR26","doi-asserted-by":"crossref","unstructured":"Tan CRC, Derkach A, Maclachlan K, et al. Real-world schedule de-escalation of teclistamab in patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42(16_suppl):7536.","DOI":"10.1200\/JCO.2024.42.16_suppl.7536"},{"key":"1149_CR27","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1158\/1078-0432.CCR-23-3333","volume":"30","author":"CPM Verkleij","year":"2024","unstructured":"Verkleij CPM, O\u2019Neill CA, Broekmans MEC, et al. T-cell characteristics impact response and resistance to T-cell-redirecting bispecific antibodies in multiple myeloma. Clin Cancer Res. 2024;30:3006\u201322.","journal-title":"Clin Cancer Res"},{"key":"1149_CR28","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood.2022015956","volume":"140","author":"N Philipp","year":"2022","unstructured":"Philipp N, Kazerani M, Nicholls A, et al. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood. 2022;140:1104\u201318.","journal-title":"Blood"},{"key":"1149_CR29","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1182\/blood.2022017726","volume":"140","author":"C Toffalori","year":"2022","unstructured":"Toffalori C, Vago L. Bispecifics need a mindful pause. Blood. 2022;140:1056\u20138.","journal-title":"Blood"},{"key":"1149_CR30","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","volume":"13","author":"N Raje","year":"2023","unstructured":"Raje N, Anderson K, Einsele H, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 2023;13:116.","journal-title":"Blood Cancer J"},{"key":"1149_CR31","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","volume":"9","author":"NS Raje","year":"2022","unstructured":"Raje NS, Anaissie E, Kumar SK, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022;9:e143\u201361.","journal-title":"Lancet Haematol."},{"issue":"1_Suppl","key":"1149_CR32","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2024-205608","volume":"144","author":"E Zamagni","year":"2024","unstructured":"Zamagni E, Silzle T, Spicka I, et al. Phase 3 study of teclistamab (tec) in combination with lenalidomide (len) and tec alone versus len alone in newly diagnosed multiple myeloma (NDMM) as maintenance therapy following autologous stem cell transplantation (ASCT): safety run-in (SRI) results from the MajesTEC-4\/EMN30 trial. Blood. 2024;144(1_Suppl):494.","journal-title":"Blood"},{"key":"1149_CR33","doi-asserted-by":"crossref","unstructured":"Touzeau C, Beksac M, Terpos E, et al. J Clin Oncol 2024;42(16_suppl):7506.","DOI":"10.1200\/JCO.2024.42.16_suppl.7506"},{"key":"1149_CR34","doi-asserted-by":"publisher","first-page":"2181016","DOI":"10.1080\/19420862.2023.2181016","volume":"15","author":"K Ball","year":"2023","unstructured":"Ball K, Dovedi SJ, Vajjah P, Phipps A. Strategies for clinical dose optimization of T cell-engaging therapies in oncology. MAbs. 2023;15:2181016.","journal-title":"MAbs"},{"key":"1149_CR35","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/psp4.12426","volume":"8","author":"G Helmlinger","year":"2019","unstructured":"Helmlinger G, Sokolov V, Peskov K, et al. Quantitative systems pharmacology: an exemplar model-building workflow with applications in cardiovascular, metabolic, and oncology drug development. CPT Pharmacomet Syst Pharmacol. 2019;8:380\u201395.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1149_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.20","volume":"4","author":"MC Peterson","year":"2015","unstructured":"Peterson MC, Riggs MM. FDA advisory meeting clinical pharmacology review utilizes a quantitative systems pharmacology (QSP) model: a watershed moment? CPT Pharmacomet Syst Pharmacol. 2015;4: e00020.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1149_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106492","volume":"187","author":"M Aghaee","year":"2023","unstructured":"Aghaee M, Ledzewicz U, Robbins M, Bezman N, Jay Cho H, Moore H. Determining optimal combination regimens for patients with multiple myeloma. Eur J Pharm Sci. 2023;187: 106492.","journal-title":"Eur J Pharm Sci"},{"key":"1149_CR38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1208\/s12248-019-0332-z","volume":"21","author":"A Betts","year":"2019","unstructured":"Betts A, Haddish-Berhane N, Shah DK, et al. A translational quantitative systems pharmacology model for CD3 bispecific molecules: application to quantify T cell-mediated tumor cell killing by P-Cadherin LP DART\u00ae. AAPS J. 2019;21:66.","journal-title":"AAPS J"},{"key":"1149_CR39","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/cts.12662","volume":"12","author":"X Chen","year":"2019","unstructured":"Chen X, Kamperschroer C, Wong G, Xuan D. A modeling framework to characterize cytokine release upon T-cell-engaging bispecific antibody treatment: methodology and opportunities. Clin Transl Sci. 2019;12:600\u20138.","journal-title":"Clin Transl Sci"},{"key":"1149_CR40","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1080\/19420862.2018.1480299","volume":"10","author":"X Jiang","year":"2018","unstructured":"Jiang X, Chen X, Carpenter TJ, et al. Development of a target cell-biologics-effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents. MAbs. 2018;10:876\u201389.","journal-title":"MAbs"},{"key":"1149_CR41","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/cpt.2729","volume":"112","author":"T Li","year":"2022","unstructured":"Li T, Hiemstra IH, Chiu C, et al. Semimechanistic physiologically-based pharmacokinetic\/pharmacodynamic model informing epcoritamab dose selection for patients with B-cell lymphomas. Clin Pharmacol Ther. 2022;112:1108\u201319.","journal-title":"Clin Pharmacol Ther"},{"key":"1149_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1208\/s12248-021-00637-2","volume":"24","author":"A Van De Vyver","year":"2021","unstructured":"Van De Vyver A, Eigenmann M, Ovacik M, et al. A novel approach for quantifying the pharmacological activity of T-cell engagers utilizing in vitro time course experiments and streamlined data analysis. AAPS J. 2021;24:7.","journal-title":"AAPS J"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01149-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01149-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01149-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T13:42:29Z","timestamp":1757166149000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01149-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1149"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01149-1","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"22 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MajesTEC-1 was funded by Johnson & Johnson.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Y.G., J.N., N.A.Q.C., S.H., Y.S., C.P.R., D.V., K.C., M.S., W.W., and N.H.B. are current employees of Johnson and Johnson and may hold stock in Johnson and Johnson. L.W. and X.M. were employees of Johnson and Johnson at the time the work was performed and may hold stock in Johnson and Johnson.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The studies were conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council for Harmonisation. The study protocols, amendments, and relevant documents were approved by the local independent ethics committee or institutional review board at each study site.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients provided written informed consent prior to treatment.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"The data sharing policy of Johnson and Johnson is available at\n                      \n                      . As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at\n                      \n                      .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Y.G., J.N., N.A.Q.C., S.H., Y.S., C.P.R., D.V., M.N.S., W.W., and N.H.B. designed the models and collected, analyzed, and interpreted the data. K.C. contributed to the clinical study design, managed the clinical study, provided clinical oversight, and analyzed and interpreted data. All authors critically reviewed and revised the manuscript and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}